Jonathan Terdiman, MD
|School||UCSF School of Medicine|
|Address||1701 Divisadero St|
San Francisco CA 94115
|Columbia University||M.D.||1989||School of Medicine|
|University of California, San Francisco||Residency ||1992||Internal Medicine|
|University of California, San Francisco||Fellowship||1993||Critical Care Medicine|
|University of California, San Francisco||Fellowship||1996||Gastroenterology|
Dr. Jonathan P. Terdiman is a Professor of Clinical Medicine and Surgery at UCSF. He earned his undergraduate degree from Princeton University in 1985 and his medical degree from the Columbia University College of Physicians and Surgeons in 1989. Dr. Terdiman completed his internal medicine residency and fellowships in both critical care medicine and gastroenterology at UCSF before joining the faculty in 1996. Dr. Terdiman currently serves as the Director of the Adult Gastroenterology Service, the Program Director of the Gastroenterology Fellowship Training Program, and Director of the Gastrointestinal Cancer Prevention Program at UCSF. Dr. Terdiman has been the recipient of numerous school-wide teaching awards and in 2013 Dr Terdiman was elected to the Department of Medicine’s Master Clinician Council. This is a rare and distinct honor and a testament to the high esteem in which Dr. Terdiman is held by his colleagues. Dr. Terdiman is considered by his peers and the community to be one of the leading practitioners of gastroenterology in the Bay area, and he serves as an invaluable resource to patients and referring providers alike. Dr. Terdiman has a reputation among his peers for taking on the most challenging cases and for his attention to detail and compassion.
Dr. Terdiman’s primary clinical and research activities are focused on the treatment of patients at high risk for gastrointestinal cancer and those with inflammatory bowel disease, though he cares for patients with a wide range of gastrointestinal diseases. He is engaged in research projects regarding how to assess and mitigate the risk of cancer among patients and families with a genetic predisposition to the disease. He also is actively engaged in projects assessing the safety and efficacy of new drugs in the treatment of inflammatory bowel disease, and recently he and his colleagues have embarked on an exciting series of studies examining the role of the microbiome in the etiology of IBD. The goal of these latter studies is to understand if manipulation of the microbiome be an important form of therapy for patients with IBD. Initial studies are focusing on the use of diet and fecal transfer to achieve these goals.
Dr Terdiman has served on the board of the Northern California Chapter of the Crohn’s and Colitis Foundation of America (CCFA) for many years, and was board president from 2010-2012. In 2012 the chapter named Dr. Terdiman as a CCFA Champion of Hope. Dr. Terdiman also is the lead author of the American Gastroenterological Association guidelines regarding the proper use of immune modulators and biological drugs in the treatment of Crohn’s disease. Dr. Terdiman is a past associate editor of the American Journal of Gastroenterology and he is a fellow of the American College of Gastroenterology and American College of Physicians.
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.